: iStockAnalyst.com Symbols Feed

Blue-Chip Biotechs Maneuver To Collect Monopoly Profits: AMGN, BIIB, GENZ

Fri, 20 Nov 2009 19:06:25 GMT

By Dr. George Huang It's hard to find winners in the nightmarish health care reform bill passed by the House... The bill doesn't address the major complaint of the American consumers – soaring costs. In fact, health insurers already predict skyrocketing premiums next year. Instead, the bill forces most employers to provide health care coverage or pay a tax penalty of up to 8% of payroll. The added cost will crush many small businesses.[More...]

Big Pharma And Biotech - Industry Outlook

Mon, 09 Nov 2009 21:58:02 GMT

The pharmaceutical industry has witnessed major changes in 2009. Performance has been affected by factors like sluggish prescription trends, intensifying generic competition and limited phase III catalysts. The next five years are expected to reflect a significant imbalance between new product introductions and patent losses.[More...]

FDA Approval for Glaxo Drug

Thu, 29 Oct 2009 13:55:13 GMT

GlaxoSmithKline (GSK) and Denmark-based Genmab received some good news with the US Food and Drug Administration’s (FDA) approval?for Arzerra (ofatumumab), a monoclonal antibody for patients with chronic lymphocytic leukemia (CLL), a slowly progressing cancer of the blood and bone marrow.?[More...]

A Positive FDA Panel Outcome for Acorda Therapeutics (NASDAQ: ACOR)

Thu, 15 Oct 2009 14:19:20 GMT

On 4/23/09, Acorda Therapeutics (NASDAQ: ACOR) announced the resubmission of its NDA for Fampridine-SR (Amaya) to the FDA as a new therapy being developed to improve walking ability in people with multiple sclerosis (MS) in response to a Refuse to File letter for the NDA issued by the Agency in late March. On 5/6/09, the FDA accepted the NDA with a priority review (six-month review) designation and a PDUFA action date of 10/22/09 as there are currently no FDA approved treatments[More...]

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): A Good Buy

Fri, 02 Oct 2009 16:55:00 GMT

On September 30, Teva Pharmaceutical Industries Ltd (TEVA), sold the worldwide rights to a generic version of the white blood-cell boosting drug filgrastim to Hospira Inc (NYSE:HSP).[More...]

Access Pharma (OTC: ACCP.OB): MuGard, Pipeline Makes for Appealing Acquisition Possibilities

Tue, 29 Sep 2009 19:31:31 GMT

Access Pharma (OTC: ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining).[More...]

FDA Calendar Updates: Orexo, Novo Nordisk, King, Isis, Facet

Mon, 10 Aug 2009 13:56:00 GMT

Below is a summary of updates to the BioMedReports.com FDA Calendar, which includes a database of 294 entries as of 8/6/09. The calendar was originally created by Mike Havrilla to track companies with pending new drug, biological agent, or medical device new product decisions at the FDA. With the launch of BioMedReports.com, the FDA Calendar has expanded to include the following categories: pending new submissions to the FDA (e.g. NDA, ANDA, BLA, 510k, PMA, sNDA, sBLA filings), pending complete (...)[More...]

Spotlight On: Biotech

Sun, 09 Aug 2009 19:06:17 GMT

Spotlight On: Biotech The U.S. biotechnology industry includes about 1,000 companies, of all sizes, with combined annual revenues close to $50 billion. Large companies include Amgen, Biogen Idec, Genetech, Genzyme, Life Technologies and Monsanto. Because so many drugs are now developed using biotechnology, the biotech and pharmaceutical industries overlap. Demand for biotechnology products and services is driven primarily by the willingness of insurers to pay for new medical treatments. With the pending introduction of Obamacare, new uncertainties are introduced to this industry. Biotech products and treatments tend to be expensive and the drive to reduce costs through rationing will no doubt effect this industry. The profitability of individual companies depends on the discovery and effective marketing of new products. Because the market for potential[More...]

Is It The Right Time To Buy Biotechnology Investments?

Thu, 30 Jul 2009 19:39:43 GMT

Share prices in the biotech sector have seen strong gains in recent weeks and it is logical to ask if it is too late to get on the biotech bandwagon. The answer, generally speaking, is no as long as investors get a few things right.[More...]

Wall Street Jumps As Technology Stocks Rally, IBM (NYSE: IBM) Soars

Thu, 16 Jul 2009 21:41:29 GMT

US stocks rallied on Thursday as better than expected initial claims data and quarterly results from JPMorgan lifted optimism.[More...]

Praxair Listed Among Top for Carbon Disclosure

Wed, 30 Sep 2009 09:48:00 GMT

Sep. 30--For the second consecutive year, Danbury-based Praxair Inc. has been rated as one of the world's top firms in the disclosure of greenhouse gas emissions.
The maker of industrial gases last week was included in the Carbon Disclosure Leadership Index's Global 500 compiled by the Carbon Disclosure Project, which recognizes 50 among 500 of the world's largest corporations as leaders in climate-change disclosure practices based on their responses to a questionnaire.
"Our selection reflects the Praxair team's ongoing commitment to continuous improvement in energy efficiency and environmental performance worldwide," Riva Krut, Praxair's director of sustainability, said in a statement.

: iStockAnalyst.com Symbols Feed

Blue-Chip Biotechs Maneuver To Collect Monopoly Profits: AMGN, BIIB, GENZ

Big Pharma And Biotech - Industry Outlook

FDA Approval for Glaxo Drug

A Positive FDA Panel Outcome for Acorda Therapeutics (NASDAQ: ACOR)

Teva Pharmaceutical Industries Limited (NASDAQ:TEVA): A Good Buy

Access Pharma (OTC: ACCP.OB): MuGard, Pipeline Makes for Appealing Acquisition Possibilities

FDA Calendar Updates: Orexo, Novo Nordisk, King, Isis, Facet

Spotlight On: Biotech

Is It The Right Time To Buy Biotechnology Investments?

Wall Street Jumps As Technology Stocks Rally, IBM (NYSE: IBM) Soars

Praxair Listed Among Top for Carbon Disclosure

Biotech Center Ready for $10.4M Expansion: Construction Set to Start Next Month on Addition to Support Job-Creation Initiatives

Bridgepoint Ed, Quiksilver, Ulta Salon big movers

Major business events scheduled for Thursday

BMI Gets Boost to Build Biodiesel Plant

AIG, General Mills, MetroPCS are big movers

Acorda shares fall on Biogen partnership

Going to Plan B: Would-Be Entrepreneurs Fight Recession With Courage and Energy

Stocks Edge Higher on Earnings News

Business Highlights - Feb 6 2009 6:55PM

Biogen Idec Increases Offer to Acquire Facet Biotech to $17.50 Per Share in Cash; Sends Letter to Facet Biotech Stockholders Describing Its Best-and-Final Offer

Analyst Choice Updated Analysis on DENTSPLY International Inc., PAETEC Holding Corp., Antigenics Inc., Cubist Pharmaceuticals Inc., Alkermes Inc. and Biogen Idec Inc.

Sunesis Reports Financial Results for the Second Quarter 2009

Biogen Idec Reports Second Quarter 2009 Results

Phillip A. Sharp to Retire from Biogen Idec Board

InvestorSoup.com Issues Trading Outlook for Hemispherex Biopharma Inc.

Finesse Solutions Forges Agreement With Leading Biotechnology Company for Single-Use Technology Exploration

Sunesis Pharmaceuticals Receives Milestone Payment From Biogen Idec

Biogen Idec Receives Fast Track Designation from FDA for PEGylated Interferon Beta-1a for Relapsing Multiple Sclerosis

Biogen Idec to Report Second Quarter 2009 Financial Results on July 16, 2009

Form 4 Hamm Robert A For: Nov 04 (10K)

Form 4 Hamm Robert A For: Nov 01 (10K)

Form 4 MacLean Michael F For: Nov 01 (10K)

Form 4 MacLean Michael F For: Oct 01 (10K)

Form 4 PICKETT CECIL B For: Oct 02 (10K)

Form 4 BIOGEN IDEC INC. For: Sep 29 Filed by: PANGIA ROBERT W (10K)

Form 4 Clancy Paul J For: Sep 04 (10K)

Form 4/A PICKETT CECIL B For: Apr 08 (10K)

Form 4 Clancy Paul J For: Aug 01 (10K)

Form 4 ALEXANDER SUSAN H For: Aug 01 (10K)